All Oncology News

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

The NAPBC has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

The marketing authorization application submitted to the EMA for T-DXd in HER2-positive unresectable or metastatic solid tumors has been validated.

Ateganosine sequenced with cemiplimab was active in advanced NSCLC after disease progression on 2 or more standard therapies.

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

GLSI-100 received fast track designation from the FDA for patients with HLA-A*02- and HER2-positive breast cancer after SOC therapy.

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Tsewang Tashi, MD, discusses how elenestinib could be an effective option with a manageable safety profile in ISM.

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

The FDA approved TAR-200 in patients with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.

Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.

Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.

Dordaviprone was included as a category 2A single agent in the NCCN guidelines for recurrent or progressive H3K27M-mutant diffuse high-grade glioma.

The FDA has provided guidance on the design of a potential phase 3 trial evaluating the ADC ozuriftamab vedotin in OPSCC.

Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.